Data Published in The Lancet Shows High Efficacy at 96 Weeks for...

Data Published in The Lancet Shows High Efficacy at 96 Weeks for...


CORK, Ireland, July 24: Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson and Johnson today announced that a regimen of two investigational long-acting, injectable formulations of HIV medicines -Janssen's rilpivirine and ViiV Healthcare's cabotegravir - given together every 4 or 8 weeks was as effective as 3-drug oral antiretroviral therapy at maintaining HIV-1 viral suppression through 96 weeks receiving injections every eight weeks, warranting further investigation. Virologic response was also achieved by 87 percent of those receiving injections every four weeks versus 84 percent receiving oral ART therapy.



from Biotech News